Anaptysbio (ANAB) EBITDA (2016 - 2026)
Anaptysbio posted quarterly EBITDA of -$53.0 million for Q1 2026, down 34.28% year-on-year from -$80.7 million in Q1 2025, and down 206.99% on a QoQ basis from $49.5 million in Q4 2025.
Anaptysbio (ANAB) has 11 years of EBITDA data on file, last reported at -$53.0 million in Q1 2026.
- For the quarter ending Q1 2026, EBITDA fell 34.28% year-over-year to -$53.0 million; the trailing twelve-month figure through Mar 2026 stood at -$27.1 million (up 80.62% YoY), and the FY2025 full-year result was -$13.6 million, up 90.59% from the prior year.
- EBITDA for Q1 2026 stood at -$53.0 million, down from $49.5 million in the prior quarter.
- Across five years, EBITDA topped out at $49.5 million in Q4 2025 and bottomed at -$53.0 million in Q1 2026.
- The 5-year median for EBITDA is -$38.3 million (2022), against an average of -$29.6 million.
- The widest annual swing landed in 2022, when EBITDA tumbled 6778.74%; it then jumped 322.79% in 2025.
- A 5-year view of EBITDA shows it stood at -$25.7 million in 2022, then tumbled by 58.5% to -$40.7 million in 2023, then soared by 45.3% to -$22.2 million in 2024, then surged by 322.79% to $49.5 million in 2025, then slumped by 206.99% to -$53.0 million in 2026.
- The last three EBITDA figures came in at -$53.0 million (Q1 2026), $49.5 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -13.63 Mn |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -14.44 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 661.60 Mn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 201.19 Mn |
| 10 | Anaptysbio | 1.60 Bn | 1.31 Bn | - | -53.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -53.01 Mn |
| Dec 31, 2025 | 49.54 Mn |
| Sep 30, 2025 | 15.17 Mn |
| Jun 30, 2025 | -38.80 Mn |
| Mar 31, 2025 | -39.47 Mn |
| Dec 31, 2024 | -22.24 Mn |
| Sep 30, 2024 | -31.68 Mn |
| Jun 30, 2024 | -46.45 Mn |
| Mar 31, 2024 | -43.76 Mn |
| Dec 31, 2023 | -40.66 Mn |
| Sep 30, 2023 | -36.05 Mn |
| Jun 30, 2023 | -40.19 Mn |
| Mar 31, 2023 | -42.28 Mn |
| Dec 31, 2022 | -25.65 Mn |
| Sep 30, 2022 | -35.65 Mn |
| Jun 30, 2022 | -33.98 Mn |
| Mar 31, 2022 | -38.27 Mn |
| Dec 31, 2021 | -32.76 Mn |
| Sep 30, 2021 | -6.69 Mn |
| Jun 30, 2021 | -494,000.00 |
| Mar 31, 2021 | -18.27 Mn |
| Dec 31, 2020 | 33.38 Mn |
| Sep 30, 2020 | -24.26 Mn |
| Jun 30, 2020 | -21.94 Mn |
| Mar 31, 2020 | -7.46 Mn |
| Dec 31, 2019 | -20.41 Mn |
| Sep 30, 2019 | -31.13 Mn |
| Jun 30, 2019 | -23.59 Mn |
| Mar 31, 2019 | -21.65 Mn |
| Dec 31, 2018 | -16.68 Mn |
| Sep 30, 2018 | -15.82 Mn |
| Jun 30, 2018 | -13.49 Mn |
| Mar 31, 2018 | -15.89 Mn |
| Dec 31, 2017 | -7.24 Mn |
| Sep 30, 2017 | -9.07 Mn |
| Jun 30, 2017 | -2.73 Mn |
| Mar 31, 2017 | -11.45 Mn |
| Dec 31, 2016 | -4.26 Mn |
| Sep 30, 2016 | -1.12 Mn |
| Jun 30, 2016 | 181,000.00 |
| Mar 31, 2016 | -888,000.00 |